These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35415706)
1. Investigation of immune response induction by Japanese encephalitis live-attenuated and chimeric vaccines in mice. Fang E; Liu X; Liu X; Li M; Wang L; Li M; Zhang Z; Li Y; Yu Y MedComm (2020); 2022 Jun; 3(2):e117. PubMed ID: 35415706 [TBL] [Abstract][Full Text] [Related]
2. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K mBio; 2020 Apr; 11(2):. PubMed ID: 32265332 [TBL] [Abstract][Full Text] [Related]
6. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea. Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480 [TBL] [Abstract][Full Text] [Related]
7. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus. Lobigs M; Larena M; Alsharifi M; Lee E; Pavy M J Virol; 2009 Mar; 83(6):2436-45. PubMed ID: 19109382 [TBL] [Abstract][Full Text] [Related]
8. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area. Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273 [TBL] [Abstract][Full Text] [Related]
9. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893 [TBL] [Abstract][Full Text] [Related]
10. T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine. Wang R; Zhen Z; Turtle L; Hou B; Li Y; Wu N; Gao N; Fan D; Chen H; An J Appl Microbiol Biotechnol; 2020 Aug; 104(15):6779-6789. PubMed ID: 32556415 [TBL] [Abstract][Full Text] [Related]
11. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine. Appaiahgari MB; Vrati S Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Guirakhoo F; Zhang ZX; Chambers TJ; Delagrave S; Arroyo J; Barrett AD; Monath TP Virology; 1999 May; 257(2):363-72. PubMed ID: 10329547 [TBL] [Abstract][Full Text] [Related]
14. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety. Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964 [TBL] [Abstract][Full Text] [Related]
15. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814 [TBL] [Abstract][Full Text] [Related]
16. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice. Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086 [TBL] [Abstract][Full Text] [Related]
17. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China. Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360 [TBL] [Abstract][Full Text] [Related]
18. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine. Bouckenooghe A; Bailleux F; Feroldi E Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children. Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242 [TBL] [Abstract][Full Text] [Related]
20. Current recommendations for the Japanese encephalitis vaccine. Chen HL; Chang JK; Tang RB J Chin Med Assoc; 2015 May; 78(5):271-5. PubMed ID: 25841620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]